IL-31 monoclonal antibody formulations

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9738715
APP PUB NO 20160311898A1
SERIAL NO

15208990

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ZYMOGENETICS INCSEATTLE WA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Beckmann, Roland Vienna, AT 39 218
Bondensgaard, Kent Vaerlose, DK 14 156

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 22, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 22, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00